A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Myeloproliferative disorders are clonal haematopoietic stem cell malignancies characterized by independency or hypersensitivity of haematopoietic progenitors to numerous cytokines. The molecular basis of most myeloproliferative disorders is unknown. On the basis of the model of chronic myeloid leukaemia, it is expected that a constitutive tyrosine kinase activity could be at the origin of these diseases. Polycythaemia vera is an acquired myeloproliferative disorder, characterized by the presence of polycythaemia diversely associated with thrombocytosis, leukocytosis and splenomegaly. Polycythaemia vera progenitors are hypersensitive to erythropoietin and other cytokines. Here, we describe a clonal and recurrent mutation in the JH2 pseudo-kinase domain of the Janus kinase 2 (JAK2) gene in most (> 80%) polycythaemia vera patients. The mutation, a valine-to-phenylalanine substitution at amino acid position 617, leads to constitutive tyrosine phosphorylation activity that promotes cytokine hypersensitivity and induces erythrocytosis in a mouse model. As this mutation is also found in other myeloproliferative disorders, this unique mutation will permit a new molecular classification of these disorders and novel therapeutical approaches.

[1]  V. Najfeld,et al.  Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected * , 2002, British journal of haematology.

[2]  J. Renauld,et al.  Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Kralovics,et al.  Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. , 2002, Experimental hematology.

[4]  S. Pestka,et al.  A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses , 1997, Molecular and cellular biology.

[5]  A. Axelrad,et al.  Letter: Bone-marrow responses in polycythemia vera. , 1974, The New England journal of medicine.

[6]  T. Clackson,et al.  JAK2, complemented by a second signal from c‐kit or flt‐3, triggers extensive self‐renewal of primary multipotential hemopoietic cells , 2002, The EMBO journal.

[7]  T. Pearson,et al.  The diagnostic criteria of polycythaemia rubra vera. , 1996, Leukemia & lymphoma.

[8]  D. Stockton,et al.  Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. , 2003, Blood.

[9]  O. Silvennoinen,et al.  JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin , 1993, Cell.

[10]  Qiong Shen,et al.  Ectopic expression of Delta4 impairs hematopoietic development and leads to lymphoproliferative disease. , 2002, Blood.

[11]  W. Vainchenker,et al.  Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. , 2003, Blood.

[12]  J. Spivak,et al.  Polycythemia vera: myths, mechanisms, and management. , 2002, Blood.

[13]  M. G. Myers,et al.  Tyrosine Phosphorylation of Jak2 in the JH2 Domain Inhibits Cytokine Signaling , 2004, Molecular and Cellular Biology.

[14]  W. Vainchenker,et al.  Erythroid progenitors in polycythemia vera: demonstration of their hypersensitivity to erythropoietin using serum free cultures. , 1982, Blood.

[15]  R Berger,et al.  A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. , 1997, Science.

[16]  W. Vainchenker,et al.  Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. , 2004, Experimental hematology.

[17]  H. Steen,et al.  Autophosphorylation of JAK2 on Tyrosines 221 and 570 Regulates Its Activity , 2004, Molecular and Cellular Biology.

[18]  J. Spivak.  The chronic myeloproliferative disorders: clonality and clinical heterogeneity. , 2004, Seminars in hematology.

[19]  J. Prchal.  Polycythemia vera and other primary polycythemias , 2005, Current opinion in hematology.

[20]  H. Lodish,et al.  The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. , 2001, Molecular cell.

[21]  K. Liedl,et al.  Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. , 2001, Protein engineering.

[22]  S. Pestka,et al.  Interferon‐γ receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death , 2001, Journal of leukocyte biology.

[23]  T. Roberts,et al.  Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways , 1997, Molecular and cellular biology.

[24]  Prchal Jf,et al.  Letter: Bone-marrow responses in polycythemia vera. , 1974 .

[25]  O. Silvennoinen,et al.  Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain , 2000, Molecular and Cellular Biology.

[26]  Mauno Vihinen,et al.  Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. , 2003, Molecular biology of the cell.

[27]  P. Marynen,et al.  Genomic organization of human JAK2 and mutation analysis of its JH2-domain in leukemia , 1999, Cytogenetic and Genome Research.

[28]  R. Berger,et al.  Partial chromosome 21 amplification in a child with acute lymphoblastic leukemia , 1995, Genes, chromosomes & cancer.